Peregrine Provides Update on Government-Sponsored Research Program

Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2011 Clinical Progress and Financial Results

Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 12th Annual Healthcare Conference

New Patents Expand Coverage for Imaging and Therapeutic Applications of Peregrine's Phospholipid-Targeting Technologies

Peregrine to Report First Quarter Fiscal Year 2011 Financial Results After Market on September 9, 2010

Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2010 Financial Results

Peregrine Initiates Second Randomized Phase IIb Lung Cancer Trial Using First-In-Class PS-Targeting Monoclonal Antibody Bavituximab

Peregrine to Report Fourth Quarter and Fiscal Year 2010 Financial Results After Market on July 14, 2010

Peregrine Pharmaceuticals Joins Russell 3000 Index

Peregrine Provides Update on Government-Sponsored Research Program